Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS   US4643301090

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

ISIS Pharmaceuticals, Inc. : Webcast Alert: Isis Pharmaceuticals' First Quarter 2013 Financial Results Conference Call

05/02/2013 | 01:00pm US/Eastern
Recommend:
0

CARLSBAD, Calif., May 2, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:

    What:   Isis Pharmaceuticals' First Quarter 2013
            Financial Results and Highlights Conference
            Call

    When:   Tuesday, May 7, 2013 at 4:30 p.m. ET /1:30
            p.m. PT

    Where: www.isispharm.com

    How:    Live on the Internet.  Simply log onto our Web
            site listed above.

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO(TM), in the United States for the treatment of patients with HoFH. Genzyme is also pursuing marketing approval of KYNAMRO in other markets. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics(TM) is a trademark of Regulus Therapeutics Inc. KYNAMRO(TM) is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals Inc.

Recommend :
0
React to this article
Latest news on ISIS PHARMACEUTICALS, INC.
2d ago ISIS PHARMACEUTICALS : Assigned Patent
04/01 ISIS PHARMACEUTICALS : to Present at the 13th Annual Needham Healthcare Conferen..
03/31 ISIS PHARMACEUTICALS : Reports Final Phase 2 Data On -APOCIII Rx In Patients Wit..
03/28 ISIS PHARMACEUTICALS : Biotech Stocks Analysis -- Research on Array BioPharma, A..
03/25 ISIS PHARMACEUTICALS : Assigned Patent
03/24 ISIS PHARMACEUTICALS : Announces Antisense Targeting Of HBV Produces Dose-Depend..
03/20 ISIS PHARMACEUTICALS : Assigned Patent
03/19 ISIS PHARMACEUTICALS : Patent Issued for Modulation of Prion Expression
03/19 ISIS PHARMACEUTICALS : Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyper..
03/12 ISIS PHARMACEUTICALS : IWM, SSG: Big ETF Inflows
Dynamic quotes  
ON
| OFF